BRD4-JAK2 Inhibitor Compounds for Dual Cancer Pathway Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack effective dual targeting agents that can inhibit both bromodomain-containing proteins (BRDs) and kinases, which are essential for treating various cancers, particularly those driven by BETs and mutant FLT3.
Innovation Solution
Development of novel compounds that act as selective inhibitors of BRD4, with dual targeting activity, to treat cancer by inhibiting both BRD4 and kinases, thereby reducing tumor growth and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer therapies use single-target inhibitors, then the treatment mechanism is simple, but the therapeutic effectiveness is insufficient for cancers driven by multiple pathways
Solution Approach 1:
The patent merges two distinct inhibitory functions into a single compound molecule. The compound simultaneously inhibits BRD4 bromodomain (epigenetic regulation) and FLT3 kinase (signal transduction), combining two therapeutic mechanisms into one agent to address multiple cancer driver pathways concurrently
Solution Approach 2:
The invention creates a multi-functional compound that performs multiple therapeutic roles: it acts as both a bromodomain inhibitor and a kinase inhibitor within a single molecular structure, enabling one drug to target multiple oncogenic pathways and provide broad-spectrum anti-cancer activity
2Reliability
If novel dual-targeting compounds are developed, then the therapeutic effectiveness is improved, but the compound structure complexity increases
Solution Approach 1:
The compound represents a composite molecular structure integrating two distinct pharmacophores: a bromodomain inhibitor moiety and a kinase inhibitor moiety. This composite structure enables simultaneous engagement of both BRD4 and FLT3 targets while maintaining a single defined chemical entity
3Measurement precision
If selective BRD4 inhibitors are used, then the specificity for BET proteins is improved, but the ability to target kinase pathways is lost
Solution Approach 1:
The compound merges selective BRD4 inhibition capability with FLT3 kinase inhibition capability into a single molecular entity, maintaining target specificity for both proteins while enabling dual pathway engagement that neither single-target inhibitor could achieve alone
Data Source
AI summary
Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I, II, and II.